WilliamLaurenceDahutMD

Hematology • Washington, DC

Hematologic Oncology

Physician

Join to view full profile

Dr. Dahut is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dahut's full profile

Already have an account?

Office
6900 Georgia Avenue NW
Washington, DC 20307
Phone+1 301-435-8183

Education & Training

National Capital ConsortiumResidency, Internal Medicine, 1985 - 1988
Georgetown University School of MedicineClass of 1985
National Capital ConsortiumFellowship, Hematology and Medical Oncology

Certifications & Licensure

MD State Medical License 1988 - 2026

Clinical Trials

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Start of enrollment: 2000 Mar 01
Completed
Phase 3
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 Sep 01
Completed
Phase 1
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy Start of enrollment: 2002 Apr 01
Completed
Phase 1
Ketoconazole Plus Docetaxel to Treat Prostate Cancer Start of enrollment: 2002 Mar 19
Completed
Phase 1
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer Start of enrollment: 2005 Apr 19
Completed
Phase 2
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
AZD2171 to Treat Prostate Cancer Start of enrollment: 2006 Oct 16
Completed
Phase 2
Satraplatin and Prednisone to Treat Prostate Cancer Start of enrollment: 2008 Feb 19
Completed
Phase 2
Data Collection, Clinical Care and Interventions in CCR, NCI Start of enrollment: 2004 Jun 10
ENROLLING_BY_INVITATION
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2009 Jul 16
Completed
Phase 2
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) Start of enrollment: 2010 Feb 23
Completed
Phase 1, Phase 2
AMG 386 and Abiraterone for Advanced Prostate Cancer Start of enrollment: 2012 Feb 08
Completed
Phase 2
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma Start of enrollment: 2012 Mar 01
Withdrawn
Phase 1
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Start of enrollment: 2012 Sep 07
Completed
Phase 1, Phase 2
Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders Start of enrollment: 2015 Jun 01
Join now to see all

Publications & Presentations

PubMed

1 citations
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
Elizabeth J Schafer, Mathieu Laversanne, Hyuna Sung, Isabelle Soerjomataram, Alberto Briganti
European Urology. 2025-03-01
2 citations
Castration Levels of Testosterone Results in Atrophy of Androgen-sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism.
Nityam Rathi, Zoë Blake, Jason Hyman, Daniel R Nemirovsky, David G Gelikman
Urology. 2025-02-01
What's in a Name? Why Words Matter in Advanced Prostate Cancer.
William K Oh, Neeraj Agarwal, Alan Bryce, Pedro Barata, Courtney Bugler
European Urology. 2025-02-01

Press Mentions

Cancer Mortality Rates Fall Among Black AmericansFebruary 23rd, 2025
Nearly 50% Drop in Black Cancer Deaths, yet Stark Disparities PersistFebruary 23rd, 2025
Cancer Death Rate for Black People Declines, but Higher Risk RemainsFebruary 21st, 2025
Join now to see all

Grant Support

The Evaluation Of Novel Therapeutics For Genitourinary MalignanciesNational Cancer Institute2010–2011
The Evaluation Of Novel Therapeutics For Genitourinary MalignanciesDivision Of Clinical Sciences - Nci2009
The Evaluation Of Novel Therapeutics For Genitourinary MalignanciesNational Cancer Institute2007–2008
Evaluation Of Novel Therapeutics For Genitourinary MaligDivision Of Clinical Sciences - Nci2003
The Evaluation Of Novel Therapeutics For Genitourinary MDivision Of Clinical Sciences - Nci2002
Evaluation Of Therapeutics For Genitourinary MalignancyDivision Of Clinical Sciences - Nci2001
Novel Therapeutics For Genitourinary MalignanciesDivision Of Clinical Sciences - Nci2000

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

WilliamLaurenceDahutMD

Dr. Dahut is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.